Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

PROTOCOL CODE: BRAJACTTG

<table>
<thead>
<tr>
<th>DOCTOR'S ORDERS</th>
<th>Ht________cm</th>
<th>Wt________kg</th>
<th>BSA________m²</th>
</tr>
</thead>
</table>

REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form.

DATE: ___________________________ To be given: ___________________________ Cycle #: ___________________________

Date of Previous Cycle:

☐ Delay treatment __________ week(s)

☐ CBC & Diff, platelets day of treatment

For Cycle 1-4, May proceed with doses as written if within 24 hours ANC greater than or equal to 1 x 10⁹/L,
Platelets greater than or equal to 100 x 10⁹/L

For Cycle 5-8, May proceed with doses as written if within 24 hours ANC greater than or equal to 1.5 x 10⁹/L, Platelets greater than 90 x 10⁹/L

Dose modification for: ☐ Hematology ☐ Other Toxicity ___________

Proceed with treatment based on blood work from ___________

PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm ___________.

dexamethasone 8 mg or 12 mg (circle one) PO 30 to 60 minutes prior to AC treatment

and select ONE of the following:

☐ ondansetron 8 mg PO 30 to 60 minutes prior to AC treatment

☐ aprepitant 125 mg PO 30 to 60 minutes prior to AC treatment on Day 1, then 80 mg PO daily on Day 2 and 3

☐ netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to AC treatment

As needed antiemetics:

☐ prochlorperazine 10 mg PO prn

☐ metoclopramide 10 mg PO prn

OR

45 Minutes Prior to PACLitaxel: dexamethasone 20 mg IV in NS 50 mL over 15 minutes

30 Minutes Prior to PACLitaxel: diphenhydramINE 50 mg IV and ranitidine 50 mg IV in NS 50 mL over 20 minutes (compatible up to 3 hrs when mixed in bag)

☐ Other:

**Have Hypersensitivity Reaction Tray and Protocol Available for Cycles 5 to 8**

CHEMOTHERAPY: (Note – continued over 2 pages)

☐ CYCLE #_________(Cycle 1-4)

DOXOrubicin 60 mg/m² x BSA = _____________mg

Dose Modification: ________% = ________ mg/m² x BSA = ___________ mg

IV push

cyclophospham ide 600 mg/m² x BSA = _____________mg

Dose Modification: ________% = ________ mg/m² x BSA = ___________ mg

IV in NS 100 to 250 mL over 20 minutes to 1 hour

*** SEE PAGE 2 FOR CHEMOTHERAPY CYCLES 5 TO 8 ***

DOCTOR'S SIGNATURE: ___________________________ UC SIGNATURE: ___________________________
**DOCTOR’S ORDERS**

**DATE:**

**OR □CYCLE #5 DAY 1 (Cycle 1 of trastuzumab and PACLitaxel)**

trastuzumab 8 mg/kg x _______ kg =__________mg IV in NS 250 mL over 1 hour 30 minutes; observe for 1 hour post infusion

Pharmacy to select trastuzumab brand as per Provincial Systemic Therapy Policy III-190

<table>
<thead>
<tr>
<th>Drug</th>
<th>Brand (Pharmacist to complete. Please print.)</th>
<th>Pharmacist Initial and Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>trastuzumab</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**CYCLE #5 DAY 2**

PACLitaxel 175 mg/m² x BSA =________ mg

Dose Modification: ________ mg/m² x BSA = __________ mg

IV in NS 250 to 500 mL (non-DEHP bag) over 3 hours. (Use non-DEHP tubing with 0.22 micron or smaller in-line filter)

**OR □CYCLE #6 DAY 1**

trastuzumab 6 mg/kg x _______ kg =__________mg IV in NS 250 mL over 1 hour; observe for 30 minutes post infusion

Pharmacy to select trastuzumab brand as per Provincial Systemic Therapy Policy III-190

<table>
<thead>
<tr>
<th>Drug</th>
<th>Brand (Pharmacist to complete. Please print.)</th>
<th>Pharmacist Initial and Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>trastuzumab</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PACLitaxel 175 mg/m² x BSA =__________ mg

Dose Modification: ________ mg/m² x BSA = __________ mg

IV in NS 250 to 500 mL (non-DEHP bag) over 3 hours. (Use non-DEHP tubing with 0.22 micron or smaller in-line filter)

**OR □CYCLE # (Cycle 7, 8) DAY 1**

trastuzumab 6 mg/kg x _______ kg =__________mg IV in 250 mL NS over 30 minutes; observe for 30 minutes post infusion (not required after 3 treatments with no reaction)

Pharmacy to select trastuzumab brand as per Provincial Systemic Therapy Policy III-190

<table>
<thead>
<tr>
<th>Drug</th>
<th>Brand (Pharmacist to complete. Please print.)</th>
<th>Pharmacist Initial and Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>trastuzumab</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PACLitaxel 175 mg/m² x BSA =__________ mg

Dose Modification: ________ mg/m² x BSA = __________ mg

IV in NS 250 to 500 mL (non-DEHP bag) over 3 hours. (Use non-DEHP tubing with 0.22 micron or smaller in-line filter)

acetaminophen 325 to 650 mg PO PRN for headache and rigors

**DOCTOR'S SIGNATURE:**

**UC SIGNATURE:**

---

BC Cancer Provincial Preprinted Order BRAJACTTG
Created: July 14th, 2005   Revised: 1 Jun 2020
<table>
<thead>
<tr>
<th>DATE:</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ Return in <strong>two</strong> weeks for Doctor if cycles 1, 2, 3, or 4</td>
</tr>
<tr>
<td>☐ Post Cycle 1 only: Book filgrastim (G-CSF) SC teaching and first dose on Day__________</td>
</tr>
<tr>
<td>Return in ☐ <strong>two</strong> weeks or ☐ <strong>three</strong> weeks for Doctor and Cycle 5 Day 1 and 2 (physician discretion)</td>
</tr>
<tr>
<td>☐ Return in <strong>three</strong> weeks for Doctor and cycle 6, 7, or 8</td>
</tr>
<tr>
<td>☐ Last Cycle. Return in <strong>three</strong> weeks for Doctor and BRAJTR (to continue single agent trastuzumab)</td>
</tr>
</tbody>
</table>

**CBC & Diff, Platelets** prior to each cycle

- **Muga Scan or Echo** prior to Cycle 5 and then every ☐ 3 months or ☐ 4 months until completion of treatment

Prior to **Cycle 5**: ALT, Bilirubin

If clinically indicated: ☐ Creatinine ☐ Muga Scan ☐ Echocardiogram

- ☐ ALT ☐ Bilirubin
- ☐ Other tests:
- ☐ Consults:
- ☐ See general orders sheet for additional requests.

**DOCTOR'S SIGNATURE:**